Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Antidepressant Role Not Settled, FDA Says; Pfizer Defends Zoloft

Executive Summary

A pooled analysis of two Zoloft clinical trials in children suggests the product is effective for pediatric depression, Pfizer said during a Sept. 9 House Energy & Commerce/Oversight Subcommittee hearing
Advertisement

Related Content

Forest Former Chief Scientific Officer Olanoff Returns As President And COO
Forest Former Chief Scientific Officer Olanoff Returns As President And COO
FDA Adult Antidepressant Suicidality Analysis Will Take At Least A Year
FDA Adult Antidepressant Suicidality Analysis Will Take At Least A Year
Antidepressant Safety Concerns Depress Zoloft; Forest, Wyeth Still Happy
Antidepressant Fallout Includes Change In FDA Pediatric Study Procedure
Antidepressant “Black Box” Decision Imminent, FDA Tells Congress
Antidepressant Suicidality Should Be Regarded As Class Risk – Cmte.
Off-Label Regulation Is One Theme Of House Antidepressant Hearing
Off-Label Regulation Is One Theme Of House Antidepressant Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS044689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel